


Milestones

- 1876 Colonel Eli Lilly opens a business to create drugs based on scientific research
- 1994 Quintiles IPO
- ○1995 PAREXEL IPO
- 01996 Covance IPO: PPD IPO
- O 1998 ICON IPO
- 1998 Quintiles becomes the first company in the industry to break the \$1 billion mark, with net revenues of \$1.19
- 2003 Quintiles is purchased by Dennis Gillings' Pharma Services Holding Inc., making Quintiles a private company
- 2008 Mergers/Acquisitions: PAREXEL and ClinPhone
- 2009 Dr. Fred Eshelman steps down as CEO of PPD
- 2010 Mergers/Acquisitions: Oracle and Phase Forward
- 2010 Sanofi and Covance sign a \$2.2 Billion deal forming a 10-year partnership
- 2011 Mergers/Acquisitions: INC and Kendle; inVentiv and i3 and Kforce and PharmaNet
- 2011 PPD is acquired by affiliates of The Carlyle Group and Hellman & Friedman, becoming a private company
- 2011 Pfizer, ICON, and PAREXEL enter a 5-year preferred provider agreement worth \$6.75 Billion
- 2012 Mergers/Acquisitions: ERT and invivodata
- 2012 Jim Ogle steps down as CEO of INC Research
- 2013 Quintiles IPO (2nd time)
- 2013 Mergers/Acquisitions: BioClinica and CoreLab; PRA and RPS: PPD and Accurian: Quintiles and Novella
- 2014 Mergers/Acquisitions: BioClinica and CCBR-SYNARC; Chiltern and Ockham; PAREXEL and ClinIntel
- 2014 INC Research and PRA IPO
- 2015 Mergers/Acquisitions: BioClinica and MediciGroup; BioClinica and Synowledge; Chiltern and Theorem; ERT and PHT; LabCorp and Covance; PAREXEL and Quantum Solutions; United Health and Optum
- 2015 Joseph Herring steps down as CEO of Covance; Dennis Gillings steps down as board chairman of Quintiles

CRO Market Size (2012-2016)

For breakdowns and future predictions, download ISR's 2015 CRO Market Size Projections 2012-2019





by mergers,

acquisitions,

geographical

The top 5

are worth

more than

traded CROs

publicly

expansions.

and

1876 Colonel Eli Lilly, a farmer turned pharmacist, opened a business to create drugs based on scientific research.



() IPO

Major Merger/Acquisition

Major Leadership Change

1974 Dennis

Gillings, future

signed the first

contract to

and data

founder of Quintiles,

outsource statistical

management for

pharmaceutical

clients. Quintiles



QUINTILES

1983 Beginning of Era

1982

1984

1985

1986

1987

1989

1990

1992



Research⁶

WORLDWIDE CLINICAL TRIALS

eurofins

premiér.

MEDPACE

1996 COVANCE.

There are currently over 1,100 CROs in the world

A history of

Clinical Development

Outsourcing

R&D Era

was founded in 1982.

IPO Era This Era is characterized by a number of CROs going public, a trend that has continued through present day.

Strategic Partnerships with Pharma

2008 Eli Lilly with Covance

2010 Bristol-Myers Sauibb with Icon and PAREXEL

2010 GlaxoSmithKline with Aptuit

2010 Eli Lilly with PAREXEL

2010 Sanofi with Covance

2011 Takeda with Covance and Quintiles

2011 Bristol-Myers Sauibb with WuXi AppTec

2011 Pfizer with ICON. and PAREXEL

2012 Astellas with **INC** Research 2015 Pfizer with